TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Jan 30, 2023 12:50 JST
Source:
Eisai
Lecanemab Receives Priority Review Status in Japan
TOKYO and CAMBRIDGE, Mass., Jan 30, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI), an anti-amyloid-beta (Abeta) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Ministry of Health, Labour and Welfare (MHLW). Priority Review in Japan is granted to new medicines recognized as having high medical utility for serious diseases, and once designated for Priority Review, the target total review period is shortened.
In Japan, Eisai submitted the manufacturing and marketing approval for lecanemab to the Pharmaceuticals and Medical Devices Agency (PMDA) on January 16, 2023. This application is based on the results of the Phase III Clarity AD study and the Phase IIb clinical study (Study 201), which demonstrated that lecanemab treatment showed a reduction of clinical decline in early AD.
Lecanemab selectively binds and eliminates soluble, toxic Abeta aggregates (protofibrils) that are thought to contribute to the neurotoxicity in AD. As such, lecanemab may have the potential to have an effect on disease pathology and to slow down the progression of the disease. The Clarity AD study of lecanemab met its primary endpoint and all key secondary endpoints with highly statistically significant results. In November 2022, the results of the Clarity AD study were presented at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) conference and simultaneously published in the New England Journal of Medicine, a peer-reviewed medical journal.
In the U.S., lecanemab was granted accelerated approval as a treatment for AD by the U.S. Food and Drug Administration (FDA) on January 6, 2023. On the same day, Eisai submitted a Supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway. In Europe, Eisai submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) on January 9, 2023 and accepted on January 26, 2023. In China, Eisai initiated submission of data for a BLA to the National Medical Products Administration (NMPA) in December 2022.
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
*Protofibrils are large Abeta aggregated soluble species of 75-500 Kd. (1),(2)
For more information, visit www.eisai.com/news/2023/news202312.html.
Source: Eisai
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
March 24 2023 12:22 JST
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting
March 23 2023 12:30 JST
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal
March 20 2023 10:18 JST
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease
March 14 2023 10:09 JST
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award
March 10 2023 14:04 JST
Eisai Certified as a 2023 Health and Productivity Management Outstanding
March 09 2023 08:07 JST
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
March 06 2023 09:58 JST
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan
March 02 2023 09:45 JST
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
February 28 2023 14:28 JST
Dissolution of Bracco-Eisai Joint Venture
February 21 2023 13:02 JST
More Press release >>
Latest Press Release
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
Mar 24, 2023 13:22 JST
Mitsubishi Corporation: PoC Launched in Portland, Oregon to Develop Smart Multifamily Apartment
Mar 24, 2023 11:02 JST
MHI and PLN Nusantara Power to Jointly Investigate Co-Firing with Hydrogen, Ammonia and Biomass in Indonesia's Power Plants
Mar 24, 2023 10:26 JST
MHI Thermal Systems to Launch 22 Models of Residential-use Room Air Conditioners for the Japanese Market in 2023 (Domestic sales only)
Mar 24, 2023 10:17 JST
Fujitsu Announces Start of Acceptance Period of Takeover Offer for GK Software
Mar 23, 2023 20:28 JST
The Hitachi Group has started a strategic cooperation with the leading operator of non-cash payments Polskie ePlatnosci in the development of software and IT systems
Mar 23, 2023 18:10 JST
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting
Mar 23, 2023 13:30 JST
Fujitsu and Osaka University develop new quantum computing architecture, accelerating progress toward practical application of quantum computers
Mar 23, 2023 11:14 JST
Fujitsu named a "Nadeshiko Brand" company for promoting women's success
Mar 22, 2023 16:45 JST
Mitsubishi XRT Concept to Debut at Bangkok International Motor Show 2023
Mar 21, 2023 15:00 JST
Toyota Launches the C+walk S in Japan, a New Form of Walking-Assistance Mobility
Mar 20, 2023 18:00 JST
Another record win for Ogier aboard the GR YARIS Rally1 HYBRID
Mar 20, 2023 14:41 JST
TOYOTA GAZOO Racing secures Sebring one-two
Mar 20, 2023 14:25 JST
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal
Mar 20, 2023 11:18 JST
Liquid Hydrogen-Powered Corolla to be Absent from Round 1 of the Super Taikyu Series at Suzuka Development to Continue for Fuji 24 Hours Race
Mar 20, 2023 09:48 JST
Mitsubishi Heavy Industries Power IDS to Upgrade Steam Turbine Generators at Incineration Plant in Taiwan
Mar 17, 2023 22:35 JST
Fujitsu Small Research Lab program strengthens industry-academia collaboration with growing global R&D network
Mar 17, 2023 10:31 JST
Fujitsu and Ochanomizu University establish new AI ethics research lab, leveraging AI technologies to promote gender equality
Mar 17, 2023 10:13 JST
TANAKA Establishes New Overseas Subsidiary in Seoul, Korea
Mar 16, 2023 11:00 JST
TANAKA Establishes New Overseas Subsidiary in Seoul, Korea
Mar 16, 2023 11:00 JST
More Latest Release >>